Selected References:
- Anghelache M, et al. 2022. Multiple sclerosis in pregnancy- current neurological considerations. Romanian Journal of Pediatrics, 71(2):55-59.
- Novartis Pharmaceuticals Corporation. 2022. Mayzent Drug Label, Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44492772-5aed-4627-bd85-e8e89f308bb3
- Ruggieri S, et al. 2022. Ponesimod in the treatment of relapsing forms of multiple sclerosis: a update on the emerging clinical data. Degenerative Neurological and Neuromuscular Disease, 12:61-73.
- Sabsabi S, et al. 2023. Clinical evaluation of siponimod for the treatment of secondary progressive multiple sclerosis: pathophysiology, efficacy, safety, patient acceptability, and adherence. Patient Preference and Adherence, 16:1307–1319.
